Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Tumor-Agnostic 2Thoracic 2Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Dexamethasone 33Lenalidomide 14pomalidomide 12daratumumab 12Bortezomib 12venetoclax 7Cyclophosphamide 7isatuximab 6Therapeutics 6trametinib 4carfilzomib 4Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3fludarabine 3dabrafenib 3Vemurafenib 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Drug Therapy 3Denosumab 3Ciprofloxacin 3Calcium Dobesilate 3ridaforolimus 2pembrolizumab 2molibresib 2liposomal amphotericin B 2fludarabine phosphate 2cobimetinib 2afuresertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × saracatinib × Plasma cell × Clear all
NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡